Monrovia, CA, United States
Monrovia, CA, United States

Time filter

Source Type

Patent
Xencor | Date: 2016-06-17

The present invention is directed to novel heterodimeric antibodies.


Patent
Xencor | Date: 2016-06-17

The present invention is directed to novel heterodimeric antibodies.


Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.


Patent
Xencor | Date: 2017-03-08

The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.


The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.


The present invention is directed to novel heterodimeric antibodies.


Patent
Xencor | Date: 2016-06-08

The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.


The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.


The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.


The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants, in particular a variant polypeptide comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising the amino acid substitution P238D as compared to said parent Fc polypeptide, wherein said numbering is according to the EU index.

Loading Xencor collaborators
Loading Xencor collaborators